The state of Massachusetts currently has 38 active clinical trials seeking participants for Dementia research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
Event-Related Potential (ERP) Components in Clinical Diagnosis
Recruiting
In this study, the investigators will use a novel electroencephalogram (EEG) system that participants will wear during a single in-person research session to investigate whether ERPs are now ready for validation as a tool clinicians can easily implement to increase diagnostic accuracy and confidence. This EEG will not be used to treat, cure, mitigate or diagnosis any disease and there will be no safety or efficacy data collected about the machine for any purpose including support of FDA submissi... Read More
Gender:
All
Ages:
Between 20 years and 90 years
Trial Updated:
03/29/2024
Locations: BU Alzheimer Disease Center, Boston, Massachusetts
Conditions: Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Recruiting
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured.
Gender:
All
Ages:
55 years and above
Trial Updated:
03/25/2024
Locations: Mass General Hospital/Harvard Medical School - Dept of Neurology, Charlestown, Massachusetts
Conditions: Dementia With Lewy Bodies
Supporting Our Caregivers In ADRD Learning (SOCIAL)
Recruiting
Building on limitations of prior research, the investigators developed the Mindful and Self-Compassionate Care Program (MASC) to help caregivers of persons with Alzheimer Disease and Related Dementias (ADRD) manage stress associated with the general caregiver experience including stress stemming from managing challenging patient behaviors. MASC teaches: (1) mindfulness skills; (2) compassion and self-compassion skills; and (3) behavioral management skills. MASC also provides psychoeducation and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Alzheimer's Disease and Related Dementias, Quality of Life, Caregiver Stress
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Brain Health Program for Older Adults With Subjective Cognitive Decline
Recruiting
The investigators will compare two brain health programs in older adults with subjective cognitive decline and lifestyle risk factors for dementia. The primary aim of the study is to determine the credibility, expectancy, feasibility, acceptability, appropriateness, fidelity, and satisfaction of the programs.
Gender:
All
Ages:
60 years and above
Trial Updated:
03/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Memory Loss (Excluding Dementia), Healthy Lifestyle, Risk Reduction Behavior
PET Imaging Evaluation of [11C]SY08
Recruiting
The overall goal of the proposed research is to evaluate the use of [11C]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of [11C]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the current study are: To determine brain uptake, distribu... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
03/11/2024
Locations: MGH, Charlestown, Massachusetts
Conditions: Parkinson's Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Healthy Controls
Objective Assessment of Behavioral Associations of Patients With Dementia
Recruiting
It is generally acknowledged that patients with dementia are best cared for at home. However, outbursts of various behavioral disturbances, e.g., combativeness, appear in most cases and often necessitate institutionalization. These outbursts are often without apparent warning, which limits preventive interventions. The measurement of the electrical activity of the skin is well-studied as an indicator of stress or agitation. The investigators propose to monitor the electrical activity of skin in... Read More
Gender:
All
Ages:
All
Trial Updated:
03/07/2024
Locations: VA Bedford HealthCare System, Bedford, MA, Bedford, Massachusetts
Conditions: Dementia, Psychomotor Agitation
A Diagnostic Test for Dementia With Lewy Bodies
Recruiting
The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
03/06/2024
Locations: Mass General Hospital, Boston, Massachusetts +2 locations
Conditions: MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
Trial-Ready Cohort-Down Syndrome (TRC-DS)
Recruiting
The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 250 participants in total including co-enrolled in the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-DS) study. Participants enrolled in the TRC-DS will undergo longitudinal cognitive and clinical assessment, genetic and biomarker testing, as well as imaging and biospecimen collection. Using these outc... Read More
Gender:
All
Ages:
Between 25 years and 55 years
Trial Updated:
03/06/2024
Locations: Massachusetts General Hospital, Co-Enrolling through ABC-DS Only, Boston, Massachusetts
Conditions: Down Syndrome, Alzheimer Disease, Dementia
Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer's Disease and Other Dementias 2.0
Recruiting
The goal of this pragmatic cluster randomized clinical trial is to compare management of suspected infection in nursing home residents with dementia The main questions it aims to answer whether residents with dementia in nursing homes randomized to use a multicomponent intervention to optimize suspected infection management ( versus usual care) use less antibiotics and fewer burdensome interventions.
Gender:
All
Ages:
Between 60 years and 106 years
Trial Updated:
02/27/2024
Locations: Hebrew SeniorLife, Boston, Massachusetts
Conditions: Dementia, Alzheimer Disease, Infections
Gamma-Induction in FrontoTemporal Dementia Trial
Recruiting
This is an interventional, sham controlled, double-blind study designed to investigate the safety, tolerability and efficacy of 40 Hz transcranial alternating current stimulation (tACS), a form of noninvasive brain stimulation, delivered for 6 weeks once daily in frontotemporal dementia (FTD) patients. Cognition, gamma EEG activity and brain metabolism via FDG-PET will be measured before and after the tACS intervention.
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
02/21/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Frontotemporal Dementia
Treating Hyperexcitability in AD With Levetiracetam
Recruiting
The aim of this study is to explore the relationship between cortical hyperexcitability, abnormalities of brain network function, and cognitive dysfunction in human patients with AD and whether administration of the antiepileptic medication levetiracetam (LEV) normalizes these measures and improves cognition.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
02/02/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment